The vaccine is under development by AstraZeneca, scientists from the University of Oxford in the United Kingdom (representation)
London:
AstraZeneca’s COVID-19 experimental vaccine was safe and produced an immune response in initial clinical trials in healthy volunteers, the data showed on Monday.
The vaccine, called AZD1222 and developed by AstraZeneca and scientists from the British University of Oxford, did not cause any serious side effects and caused immune responses of antibodies and T lymphocytes, according to the results of tests published in the The Lancet medical journal.
“We hope this means that the immune system will remember the virus so that our vaccine can protect people for an extended period of time,” said lead study author Andrew Pollard of the University of Oxford.
“However, we need more research before we can confirm that the vaccine is effective in protecting against SARS-CoV-2 (COVID-19) infection, and for how long all protection lasts,” he said. he declares.
AstraZeneca is among the leading vaccine candidates for a pandemic that has claimed the lives of more than 600,000 people, alongside others in mid-term and advanced trials.
These include plans developed by the Chinese company Sinovac Biotech, another by the Chinese state-owned Sinopharm and one by the American biotechnology company Moderna.
AstraZeneca has signed agreements with governments around the world to provide the vaccine if it proves effective and obtains regulatory approval. The company said it would not seek to profit from the vaccine during the pandemic.
The researchers said the vaccine caused minor side effects more frequently than a control group, but some of them could be reduced by taking paracetamol, without serious adverse events due to the vaccine.
(With the exception of the title, this story was not edited by GalacticGaming staff and is published from a syndicated feed.)
